The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•17 April 2026•

1 min read

Agenus Reports Positive Phase II Data for Gastroesophageal Cancer Combination Therapy

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Agenus announced positive Phase II data from a trial combining botensilimab, balstilimab, and agenT-797 for PD-1 refractory gastroesophageal adenocarcinoma.

Agenus Inc. (Nasdaq: AGEN) has announced positive Phase II clinical trial data for a combination therapy featuring botensilimab, balstilimab, and agenT-797. The trial specifically targeted patients with advanced gastroesophageal adenocarcinoma who are refractory to standard PD-1 treatments. Presented at the American Association for Cancer Research (AACR) conference, the data demonstrated significant immune reprogramming and durable survival rates in this hard-to-treat population. This clinical milestone addresses a critical unmet need for patients with limited therapeutic options. The successful Phase II results strengthen Agenus's oncology pipeline and provide a foundation for potential future regulatory discussions. Market participants are closely watching for the transition into Phase III trials, which will be essential for commercial validation.